Mineralys Therapeutics Inc
MLYS45.630USD
+1.130+2.54%
交易中 （美東）報價延遲15分鐘
3.00B總市值
虧損本益比TTM
關於 Mineralys Therapeutics Inc 公司
Mineralys Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發針對高血壓、慢性腎病 (CKD) 和其他由醛固酮異常升高引起的疾病的藥物。該公司的候選產品 lorundrostat 是一種專有的口服高選擇性醛固酮合酶抑制劑 (ASI)，該公司最初正在開發用於治療不受控制的高血壓 (uHTN) 患者。Lorundrostat 旨在通過抑制負責產生激素的酶 CYP11B2 來降低醛固酮水平。該公司完成了 Target-HTN 試驗，這是一項針對 lorundrostat 治療 uHTN 的 II 期概念驗證試驗。除了高血壓之外，該公司還打算開發用於治療慢性腎病 (CKD) 的 lorundrostat。
Mineralys Therapeutics Inc簡介
公司代碼MLYS
公司名稱Mineralys Therapeutics Inc
上市日期Feb 10, 2023
CEOMr. Jon Congleton
員工數量51
證券類型Ordinary Share
年結日Feb 10
公司地址150 N. Radnor Chester Road
城市RADNOR
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編19087
電話18883786240
網址https://mineralystx.com/
公司代碼MLYS
上市日期Feb 10, 2023
CEOMr. Jon Congleton
Mineralys Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
663.52K
-2.23%
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
51.95K
-17.16%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
Dr. Derek DiRocco, Ph.D.
Dr. Derek DiRocco, Ph.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
663.52K
-2.23%
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
51.95K
-17.16%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 11月7日 週五
更新時間: 11月7日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Catalys Pacific, LLC
11.79%
RA Capital Management, LP
9.70%
Samsara BioCapital, LLC
7.51%
SR One Capital Management, LP
4.14%
The Vanguard Group, Inc.
3.98%
其他
62.88%
持股股東
持股股東
佔比
Catalys Pacific, LLC
11.79%
RA Capital Management, LP
9.70%
Samsara BioCapital, LLC
7.51%
SR One Capital Management, LP
4.14%
The Vanguard Group, Inc.
3.98%
其他
62.88%
股東類型
持股股東
佔比
Venture Capital
33.14%
Investment Advisor
26.65%
Hedge Fund
19.68%
Investment Advisor/Hedge Fund
14.86%
Private Equity
5.26%
Individual Investor
1.82%
Research Firm
1.60%
Bank and Trust
0.16%
Pension Fund
0.13%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
315
76.75M
101.61%
+1.04M
2025Q2
287
68.74M
105.48%
+8.03M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Catalys Pacific, LLC
8.90M
11.79%
--
--
Jun 30, 2025
RA Capital Management, LP
7.32M
9.7%
+1.18M
+19.14%
Sep 04, 2025
Samsara BioCapital, LLC
5.67M
7.51%
--
--
Sep 04, 2025
SR One Capital Management, LP
3.13M
4.14%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.32M
3.07%
+283.58K
+13.93%
Jun 30, 2025
Capital International Investors
2.90M
3.84%
+2.90M
--
Jun 30, 2025
Andera Partners S.A.S.
2.77M
3.66%
-100.00K
-3.49%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.74M
3.62%
+532.75K
+24.18%
Jun 30, 2025
Integral Health Asset Management, LLC
2.70M
3.57%
+400.00K
+17.39%
Jun 30, 2025
Capital World Investors
2.90M
3.84%
+2.90M
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Simplify Health Care ETF
6.55%
Invesco Dorsey Wright Healthcare Momentum ETF
2.36%
Virtus LifeSci Biotech Clinical Trials ETF
1.83%
Invesco Dorsey Wright SmallCap Momentum ETF
0.54%
SPDR S&P Biotech ETF
0.31%
iShares Micro-Cap ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.26%
Invesco Nasdaq Biotechnology ETF
0.25%
Optimize Strategy Index ETF
0.24%
Vanguard US Momentum Factor ETF
0.19%
查看更多
Simplify Health Care ETF
佔比6.55%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比2.36%
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.83%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.54%
SPDR S&P Biotech ETF
佔比0.31%
iShares Micro-Cap ETF
佔比0.28%
ProShares Ultra Nasdaq Biotechnology
佔比0.26%
Invesco Nasdaq Biotechnology ETF
佔比0.25%
Optimize Strategy Index ETF
佔比0.24%
Vanguard US Momentum Factor ETF
佔比0.19%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
